Details for Patent: 10,729,653

Which drugs does patent 10,729,653 protect, and when does it expire?

Patent 10,729,653 protects BRIVIACT and is included in one NDA.

This patent has twenty-seven patent family members in twenty-two countries.

Summary for Patent: 10,729,653

Title:	Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives
Abstract:	The present invention relates to an immediate release formulation of pharmaceutical compounds.
Inventor(s):	Cuypers; Serge (Brussels, BE), Berwaer; Monique (Brussels, BE), Fanara; Domenico (Brussels, BE), Barillaro; Valery (Brussels, BE)
Assignee:	UCB BIOPHARMA SRL (Brussels, BE)
Application Number:	13/146,074
Patent Claim Types: see list of patent claims	Composition; Compound; Dosage form;

Drugs Protected by US Patent 10,729,653

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Ucb Inc	BRIVIACT	brivaracetam	TABLET;ORAL	205836-001	May 12, 2016		RX	Yes	No			Y
Ucb Inc	BRIVIACT	brivaracetam	TABLET;ORAL	205836-002	May 12, 2016		RX	Yes	No			Y
Ucb Inc	BRIVIACT	brivaracetam	TABLET;ORAL	205836-003	May 12, 2016		RX	Yes	No			Y
Ucb Inc	BRIVIACT	brivaracetam	TABLET;ORAL	205836-004	May 12, 2016		RX	Yes	No			Y

Foreign Priority and PCT Information for Patent: 10,729,653

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	09100083	Jan 29, 2009

PCT Information
PCT Filed	January 27, 2010	PCT Application Number:	PCT/EP2010/050892
PCT Publication Date:	August 26, 2010	PCT Publication Number:	WO2010/094535

International Family Members for US Patent 10,729,653

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2010215646
Brazil	PI1007161
Canada	2747395
China	102292071